Latest news with #Northbridge
Yahoo
6 days ago
- Business
- Yahoo
EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments
– Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient interest – – Topline 56-week data for LUGANO on track for readout in mid-2026 with LUCIA topline data to closely follow – – Northbridge, MA commercial manufacturing facility on line with DURAVYU registration batches underway – – $256 million of cash, cash equivalents and marketable securities as of June 30, 2025, provides cash runway into 2027, beyond topline data for both Phase 3 wet AMD trials – WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the second quarter ended June 30, 2025, and highlighted recent corporate developments. 'In recent months, we continued our track record of exceptional execution across all aspects of the business, most notably completing enrollment in both pivotal Phase 3 trials, LUGANO and LUCIA, in wet AMD in record time for this indication,' said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint. 'The noteworthy physician and patient enthusiasm we have seen for our Phase 3 program across U.S. and international sites—supported by DURAVYU's robust Phase 2 efficacy and safety data package and our patient-centric, well-understood trial design—has reinforced the clear need and global demand for more durable wet AMD therapies and the role that DURAVYU can play in meaningfully extending the wet AMD treatment paradigm.' Dr. Duker continued, 'With topline LUGANO data anticipated in mid-2026, LUCIA data to closely follow, and registration batches underway at our state-of-the-art, commercial manufacturing facility in Northbridge, Massachusetts, we believe we are well-positioned for DURAVYU to be first-to-market among investigational sustained release treatments for wet AMD. We look forward to providing an update on our DURAVYU pivotal plan in DME in the coming months as we work to deliver innovative therapeutics for multiple serious retinal diseases.' R&D Highlights and Updates Completed enrollment of Phase 3 wet AMD pivotal program ahead of plan. LUGANO and LUCIA are double-masked non-inferiority trials designed to support a clear approval pathway and potential commercial success. Both Phase 3 trials experienced unprecedented enrollment exceeding observed recruitment rates of comparable historical and ongoing wet AMD clinical trials The oversubscribed LUGANO trial randomized 432 patients in the U.S. in seven months with topline data anticipated in mid-2026. LUCIA randomized over 400 patients in the U.S. and in ex-U.S. sites over a seven-month period, with topline data anticipated in the second half of 2026. Enrolled the first ex-U.S. patient in the LUCIA trial in Israel with patient participation in sites throughout the Czech Republic, South America, Europe, Australia and India. Investigator and patient enthusiasm for the trials underscores the retinal community's support and recognition of the clinical rigor underpinning the Phase 3 pivotal program. Announced that based on interim masked safety data, the safety profile observed in LUGANO and LUCIA is consistent with previous DURAVYU clinical trials. In parallel, an independent Data Safety Monitoring Committee ('DSMC') convened and recommended continuation of the program as planned. Received approval of the Phase 3 protocols for the LUGANO and LUCIA trials by the European Medicines Agency (EMA). Delivered multiple oral presentations at the American Society of Retina Specialists (ASRS) annual meeting supporting DURAVYU's potentially best-in-class therapeutic profile as a sustained release tyrosine kinase inhibitor (TKI) being developed for multiple indications: An assessment of the treatment burden in wet AMD treated with DURAVYU versus aflibercept from the Phase 2 DAVIO 2 clinical trial Vision outcomes from the DAVIO 2 trial for the treatment of neovascular age-related macular degeneration 24-week results from the Phase 2 VERONA clinical trial of DURAVYU versus aflibercept for the treatment of diabetic macular edema (DME) Completed a positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss pivotal Phase 3 clinical trial plans for DURAVYU in DME. The Company will share details on its DME pivotal plan in the second half of 2025. Presented 24-week topline results from the Phase 2 VERONA study in DME at the Retina World Congress in May 2025, highlighting DURAVYU's potential to transform the treatment landscape in DME, the second largest retinal disease market, with its best-in-class safety and efficacy profile. Accepted to present the Phase 2 VERONA 24-week end-of-study results in DME at the Retina Society Annual Meeting in September, underscoring the broad treatment potential of DURAVYU and enthusiasm from the retinal community for new treatment options in multiple serious retinal diseases. Recent Corporate Highlights Initiated DURAVYU registration batches in support of a potential NDA filing at EyePoint's commercial manufacturing facility in Northbridge, Massachusetts. The 41,000-square-foot facility was built to meet both FDA and EMA standards and will have capacity to support the anticipated significant demand for DURAVYU, if approved. Review of Results for the Second Quarter Ended June 30, 2025 For the second quarter ended June 30, 2025, total net revenue was $5.3 million compared to $9.5 million for the quarter ended June 30, 2024. Net revenue from license and royalties for the second quarter ended June 30, 2025, totaled $5.3 million compared to $8.4 million in the corresponding period in 2024. The decrease was primarily driven by lower recognition of deferred revenue related to the Company's 2023 agreement for the license of YUTIQ® product rights. Operating expenses for the second quarter ended June 30, 2025, totaled $67.6 million versus $44.0 million in the prior year period. This increase was primarily driven by an increase in clinical trial costs related to ongoing DURAVYU™ Phase 3 clinical trials (LUGANO and LUCIA) for wet AMD. Net non-operating income totaled $2.9 million and net loss was $59.4 million, or ($0.85) per share, compared to a net loss of $30.8 million, or ($0.58) per share, for the corresponding period in 2024. Cash, cash equivalents, and marketable securities as of June 30, 2025 totaled $256 million compared to $371 million as of December 31, 2024. Financial Outlook EyePoint expects its cash, cash equivalents, and marketable securities as of June 30, 2025 will enable the Company to fund operations into 2027 beyond topline Phase 3 data for DURAVYU in wet AMD expected in 2026. Conference Call Information EyePoint management will host a conference call today at 8:30 a.m. ET to discuss the results for the second quarter ended June 30, 2025, and recent corporate developments. To access the live conference call, please register using the audio conference link: A live audio webcast of the event can be accessed via the Investors section of the Company website at A webcast replay will also be available on the corporate website at the conclusion of the call. About EyePoint EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company's lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data to date, DURAVYU is currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) with topline data anticipated in 2026. DURAVYU also completed a positive Phase 2 clinical trial in diabetic macular edema (DME) with Phase 3 pivotal planning underway. Despite current therapies, patients with wet AMD and DME still tend to lose vision in the long term and wet AMD is the leading cause of vision loss among people 50 years of age and older in the United States. The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation. EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan. DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product candidate; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain. Forward Looking Statements EYEPOINT SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding our expectations regarding our clinical development and regulatory plans of DURAVYU; our belief that DURAVYU is on track to be the first-to-market of the current investigational sustained release treatments for wet AMD; our belief that DURAVYU has two potential blockbuster indications; our belief that DURAVYU's potential real-world application in multiple retinal disease indications and de-risked trial designs position DURAVYU for clinical and commercial success; our expectations regarding timing for the completion of clinical trial enrollment and the timing of the availability and release of clinical data; our belief that rapid trial enrollment in LUGANO and LUCIA highlights physician and patient enthusiasm for DURAVYU, which we believe is driven by an established and familiar trial design, robust Phase 2 data, and a strong safety profile; our expectations regarding cash runway; our optimism that that DURAVYU has the potential to shift the treatment paradigm in wet AMD and DME and improve patient outcomes; our expectations regarding clinical development of our other product candidates, including EYP-2301; our belief that we are well positioned as the leader in ocular sustained drug delivery; our business strategies and objectives; and other statements regarding the Company's future plans, objectives, strategies and beliefs, as identified by words such as 'will,' 'potential,' 'could,' 'can,' 'believe,' 'intends,' 'continue,' 'plans,' 'expects,' 'anticipates,' 'estimates,' 'may,' or other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint's actual results to be materially different than those expressed in or implied by EyePoint's forward-looking statements. For EyePoint, these risks and uncertainties include the timing, progress and results of the Company's clinical development activities, including DURAVYU; uncertainties and delays relating to communications with the U.S. Food and Drug Administration and the ability to obtain regulatory approval from FDA for the commercialization of DURAVYU; unanticipated costs and expenses; the Company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the risk that results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change as more data becomes available; unexpected safety or efficacy data observed during clinical trials; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for approval of the Company's product candidates; changes in the regulatory environment; disruptions at the FDA, including due to a reduction in the FDA's workforce and/or inadequate funding for the FDA; changes in U.S. and international trade policies; changes in expected or existing competition; the success of current and future license agreements; our dependence on contract research organizations, and other outside vendors and service providers; product liability; the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; delays, interruptions or failures in the manufacture and supply of our product candidates; the availability of and the need for additional financing; the Company's ability to obtain additional funding to support its clinical development programs; uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney's Office for the District of Massachusetts; uncertainties regarding the FDA warning letter pertaining to the Company's Watertown, MA manufacturing facility; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. A more complete discussion of the risks and uncertainties that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, in our other filings with the Securities and Exchange Commission (SEC) and in our future reports to be filed with the SEC, which are available at Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors: Tanner Kaufman / Jenni LuFTI Consulting Direct: 203-722-8743 / / Media Contact: Amy PhillipsGreen Room CommunicationsDirect: 412-327-9499aphillips@ PHARMACEUTICALS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (In thousands) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 71,143 $ 99,704 Marketable securities 184,590 271,209 Accounts and other receivables, net 625 607 Prepaid expenses and other current assets 6,215 9,481 Inventory 2,678 2,305 Total current assets 265,251 383,306 Operating lease right-of-use assets 21,089 21,000 Other assets 14,807 14,159 Total assets $ 301,147 $ 418,465 Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued expenses $ 31,163 $ 29,824 Deferred revenue — 17,784 Other current liabilities 2,012 1,440 Total current liabilities 33,175 49,048 Deferred revenue - noncurrent — 10,853 Operating lease liabilities - noncurrent 21,815 21,858 Other noncurrent liabilities 148 205 Total liabilities 55,138 81,964 Stockholders' equity: Capital 1,222,814 1,208,489 Accumulated deficit (977,637 ) (873,016 ) Accumulated other comprehensive income 832 1,028 Total stockholders' equity 246,009 336,501 Total liabilities and stockholders' equity $ 301,147 $ 418,465 EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Revenues: Product sales, net $ — $ 1,068 $ 715 $ 1,726 License and collaboration agreements 5,333 7,782 16,382 18,345 Royalty income — 627 12,689 1,090 Total revenues 5,333 9,477 29,786 21,161 Operating expenses: Cost of sales 165 1,401 970 2,160 Research and development 55,498 29,822 114,072 60,011 Sales and marketing 35 50 70 56 General and administrative 11,862 12,750 25,738 26,801 Total operating expenses 67,560 44,023 140,850 89,028 Loss from operations (62,227 ) (34,546 ) (111,064 ) (67,867 ) Other income (expense): Interest and other income, net 2,894 3,720 6,536 7,757 Total other income, net 2,894 3,720 6,536 7,757 Net loss before provision for income taxes $ (59,333 ) $ (30,826 ) $ (104,528 ) $ (60,110 ) Provision for income taxes (93 ) — (93 ) — Net loss $ (59,426 ) $ (30,826 ) $ (104,621 ) $ (60,110 ) Net loss per common share - basic and diluted $ (0.85 ) $ (0.58 ) $ (1.50 ) $ (1.13 ) Weighted average common shares outstanding - basic and diluted 69,926 53,206 69,847 53,059 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
10-07-2025
- Business
- Cision Canada
GoSecure Partners with Northbridge Financial to Provide Incident Preparation and Response Services Français
MONTREAL, July 10, 2025 /CNW/ - GoSecure, a leader in managed cybersecurity and professional cybersecurity services, is pleased to announce a strategic partnership with Northbridge Financial Corporation, a commercial insurance leader and cyber insurance provider in Canada. GoSecure will serve the commercial customers of Northbridge's insurance brands, Northbridge Insurance and Federated Insurance. Northbridge and Federated's commercial Cyber policyholders will gain direct access to GoSecure's dedicated 24/7 incident response helpline, expert consultation, and proactive tools to help prevent and manage cyber incidents. "This partnership marks a major step forward in bringing world-class cybersecurity support to businesses of all sizes," said Neal Creighton, CEO of GoSecure. "By serving as Northbridge customer's first call for cyber incidents, we are reinforcing our commitment to proactive threat defense and rapid response. We look forward to delivering the highest level of protection to their Cyber policyholders." This agreement is just the beginning of GoSecure's expansion into the cyber insurance sector. In addition to providing immediate support to Northbridge and Federated's commercial customers during a cyber incident, eligible policyholders will benefit from proactive services such as cybersecurity self-assessments, vulnerability scans, and follow-up consultations. Qualifying customers may also access cyber incident simulation (tabletop exercises) designed to test response readiness and strengthen incident preparedness. "As cyber threats continue to escalate, businesses need a trusted partner who can help them navigate incidents in real time," said Scott Vandenberg, Vice-President, Corporate Research and Development, at Northbridge. "At Northbridge, it's important to us that our customers are offered proactive support to help prevent cyber incidents from happening, as well as access to immediate, expert-driven guidance to mitigate damage, contain threats, and recover quickly." For more information about GoSecure solutions, visit GoSecure is a recognized cybersecurity leader offering advanced Managed Extended Detection and Response (MXDR) and expert professional services. GoSecure Titan ® managed security solutions deliver multi-vector protection with industry-leading response times across networks, endpoints, and inboxes. For over 20 years, GoSecure has helped organizations close security gaps, reduce risk, and strengthen their overall posture. About Northbridge Financial Corporation: Northbridge Financial Corporation is a leading commercial property and casualty insurance company that has helped protect Canadian businesses for more than 100 years. We offer a wide range of innovative solutions to Canadian businesses through our Northbridge Insurance, Federated Insurance, and TruShield Insurance brands. We are proud to be a 100% Canadian company, wholly-owned by Fairfax Financial Holdings. Visit us at to learn more.
Yahoo
01-06-2025
- General
- Yahoo
Mass. man killed in accidental shooting remembered as ‘accomplished cook'
A 36-year-old man who police say was accidentally killed by his brother in a shooting at a Northbridge home last month is being remembered as 'an accomplished cook.' Northbridge resident Jonathan Lacour was killed by his brother, 33-year-old Northbridge resident Christopher Lacour, on May 21, according to court documents. Christopher Lacour is charged with assault and battery with a dangerous weapon in connection with the shooting. Police were called to 63 Legion Way in Northbridge around 11 p.m. on May 21 and found Jonathan Lacour with a gunshot wound in his lower chest, according to the police report in the case. His brother, Christopher Lacour, admitted to pulling the trigger on him, but said the shooting was an accident. Read more: Man killed brother in what appears to be accidental shooting in Northbridge home Jonathan 'Jon' Scott Lacour was born to 'his loving mother and father,' Darlene Perreault and Roger Lacour, on Jan. 7, 1989, according to his obituary. He studied culinary arts at Blackstone Valley Regional Technical High School and was working at Kapi's Pub in Uxbridge when he died. 'Jon was a gentle, unassuming man with an old soul. He was a homebody who truly enjoyed and appreciated the simple things in life,' his obituary reads. Jonathan Lacour was also an animal lover who enjoyed petsitting his family members' pets, according to his obituary. Read more: Man faces assault charge in Northbridge fatal shooting 'A good week for Jon would include working, fishing, reading and listening to music, especially his favorite band, Pink Floyd. But more than anything, he enjoyed time at home socializing with family and friends,' his obituary reads. Jonathan Lacour leaves behind his parents, three brothers, stepparents, step siblings and many other beloved friends and relatives, according to his obituary. Calling hours for Jonathan Lacour are scheduled for Thursday, June 5, from 4 p.m. to 7 p.m. at Roney Funeral Home in North Grafton, according to his obituary. In lieu of flowers, his family asks that his memory be honored through donations to the Worcester Animal Rescue League. Holyoke police to cite driver who heavily damaged JFK memorial while driving under the influence Man charged with murder after woman's body is discovered near Northeastern University Rockport fire captain who died unexpectedly remembered for his service to the town 2nd victim in Boston double shooting from last weekend dies, both men identified Gov. Healey demands answers after ICE arrests Mass. high school student Read the original article on MassLive.
Perth Now
23-05-2025
- Perth Now
The ultimate comfort food: Perth's best Char Kway Teow
North Perth We can't get enough of the food from this hole-in-the-wall eatery on Angove street. The char kway teow (or as they call it, the C.K.T) is a delicious mess of smoky noodles, bean sprouts and pork sausage. Thornlie Located inside the famous foodie destination of Spencer Village, it's got some tough competition for your tastebuds. But with its delicious smoky flavours, there is a good reason this should be on the menu for any Spencer Village visit. Northbridge The Penang-style char kway teow is a signature dish at this Malaysian eatery, and when they say it is their most popular fired dish — we believe them. Choose between chicken, beef, seafood, or vegetarian, but just make sure you add it to your order. Willetton West Leedy's loss is Willetton's gain as this popular Singaporean and Malaysian eatery has picked up sticks and decamped to the southern suburbs. The char kway teow with tiger prawns, fish cake slices and Chinese sausage remains on the menu along with all the other favs at this restaurant with a cult following. Morley If I was a deep undercover international spy and needed a discrete meeting place where no one would think to look, Mamak House would be top of the list. What I'm saying is, it's not the most likely location for a rendezvous, or a topnotch Malaysian restaurant for that matter. Luckily, those who know , know that this is a top spot for very very good food including a char kway teow to knock your socks off.
CBS News
22-05-2025
- CBS News
Possible accidental gun discharge investigated after man is killed in Massachusetts home
A Massachusetts man was charged after another man was found shot to death at a home in Northbridge late Wednesday night and police are investigating it as a possible accidental gun discharge. Worcester County District Attorney Joseph Early said police were called to a home on Legion Way shortly after 11 p.m. Wednesday. At the home, a 36-year-old man was found dead with a single gunshot wound. His name has not been released. Man arrested at Northbridge home "We didn't see or hear the gunshot but afterwards, we had quite a few...I guess there was a state and a town police car here," said neighbor Phil Greiner. "The younger of their two boys came out and I guess they took him into custody but I don't know that for sure." Christopher Lacour, 33, was arrested at the home and charged with assault and battery with a dangerous weapon. He was arraigned Thursday in Uxbridge District Court and released on $10,000 bail. Police said he had a license to carry the gun, which has now been suspended. Gun safety reminder from DA Police said Lacour and the victim knew each other and were related but didn't say how. They added the shooting was an "isolated incident" and the public is not at risk. They said this is a lesson in gun safety. "Never underestimate the discussion you have to have with regards to gun safety," said Early. "I am comfortable saying that right now, not too much more really we can say, we've got to say in the courtroom." An autopsy is pending with the results expected to be released Friday. Police said the charges against Lacour could be upgraded once the autopsy's results are released. He is due bac in court on June 23. A man at the home where this happened told WBZ-TV he can't say anything before asking the news crew to leave.
